However, significant heterogeneity exists among HER2-positive breast cancer patients as evidenced by the fact that some HER2-positive breast cancer patients exhibit de novo trastuzumab resistance, it is therefore necessary to identify the predictive markers. Here, ERBB2 is linked to breast carcinoma.